Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study
- PMID: 27772531
- PMCID: PMC5075753
- DOI: 10.1186/s12916-016-0703-6
Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study
Abstract
Background: Neuregulin 4 (Nrg4) is a secreted adipokine recently identified as playing an important role in modulating systemic energy metabolism and the development of obesity-associated disorders. However, information is not available regarding the association between circulating Nrg4 and risk of metabolic syndrome (MetS) in humans.
Methods: We measured serum Nrg4 in 1212 obese adult subjects (aged 40 years or older), with a waist circumference greater than 90 cm for men or 80 cm for women, recruited from the community.
Results: MetS subjects had lower levels of circulating Nrg4 than healthy controls (P < 0.01). The prevalence of MetS was higher in subjects with lower levels of circulating Nrg4 compared to those with higher values (67.3 % vs. 57.4 %, P < 0.05). Likewise, subjects with low levels of circulating Nrg4 had high prevalence of raised fasting glucose and blood pressure, but there was no association with raised triglycerides and reduced HDL-c. In multivariable logistic regression analyses, increased serum Nrg4 was significantly associated with reduced risk of MetS (OR: 0.603; 95 % CI, 0.439-0.828; P = 0.002), adjusting for age, gender, current smoking, alcohol consumption, physical activity, BMI, systolic blood pressure, fasting glucose, triglyceride, HDL-c, HOMA-IR, and body fat mass; however, such associations with serum Nrg4 were not noted for each component of MetS.
Conclusions: These findings indicate that circulating Nrg4 concentrations are inversely associated with risk of MetS in obese Chinese adults, suggesting that circulating Nrg4 concentrations may be a protective factor in the development of MetS.
Keywords: Body fat mass; Metabolic syndrome; Neuregulin 4; Obesity.
Figures

Similar articles
-
Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults.Sci Rep. 2016 Nov 7;6:36710. doi: 10.1038/srep36710. Sci Rep. 2016. PMID: 27819316 Free PMC article.
-
Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.J Obstet Gynaecol. 2019 Oct;39(7):975-980. doi: 10.1080/01443615.2019.1581754. Epub 2019 May 7. J Obstet Gynaecol. 2019. PMID: 31064233
-
Plasma Neuregulin 4 Levels Are Associated with Metabolic Syndrome in Patients Newly Diagnosed with Type 2 Diabetes Mellitus.Dis Markers. 2018 Mar 12;2018:6974191. doi: 10.1155/2018/6974191. eCollection 2018. Dis Markers. 2018. PMID: 29721105 Free PMC article.
-
A systematic review of the association of neuregulin 4, a brown fat-enriched secreted factor, with obesity and related metabolic disturbances.Obes Rev. 2020 Feb;21(2):e12952. doi: 10.1111/obr.12952. Epub 2019 Nov 28. Obes Rev. 2020. PMID: 31782243
-
Neuregulin 4 as a novel adipokine in energy metabolism.Front Physiol. 2023 Jan 10;13:1106380. doi: 10.3389/fphys.2022.1106380. eCollection 2022. Front Physiol. 2023. PMID: 36703934 Free PMC article. Review.
Cited by
-
Association between circulating neuregulin4 levels and diabetes mellitus: A meta-analysis of observational studies.PLoS One. 2019 Dec 9;14(12):e0225705. doi: 10.1371/journal.pone.0225705. eCollection 2019. PLoS One. 2019. PMID: 31815951 Free PMC article.
-
Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands.Front Physiol. 2020 Apr 21;11:354. doi: 10.3389/fphys.2020.00354. eCollection 2020. Front Physiol. 2020. PMID: 32372975 Free PMC article. Review.
-
Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside.Protein Cell. 2025 Aug 7;16(8):641-666. doi: 10.1093/procel/pwaf027. Protein Cell. 2025. PMID: 40243151 Free PMC article. Review.
-
Roux-en-Y-Bariatric Surgery Reduces Markers of Metabolic Syndrome in Morbidly Obese Patients.Obes Surg. 2020 Feb;30(2):391-400. doi: 10.1007/s11695-019-04190-y. Obes Surg. 2020. PMID: 31728904
-
The Impact of Neuregulin 4 on Metabolic Dysregulation in Lipodystrophy.Endocrinology. 2025 Jul 8;166(9):bqaf112. doi: 10.1210/endocr/bqaf112. Endocrinology. 2025. PMID: 40580113 Free PMC article.
References
-
- Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50. doi: 10.1161/01.CIR.0000140677.20606.0E. - DOI - PubMed
-
- Liu L, Miura K, Fujiyoshi A, Kadota A, Miyagawa N, Nakamura Y, Ohkubo T, Okayama A, Okamura T, Ueshima H. Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the United States and in Japan. Am J Cardiol. 2014;113(1):84–9. doi: 10.1016/j.amjcard.2013.08.042. - DOI - PubMed
-
- Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. doi: 10.1016/j.jacc.2013.11.004. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical